Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)

References

• Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146(1):196–8. doi:10.1016/j.ygyno.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Bruni LAG, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC information centre on HPV and cancer (HPV information centre) human papillomavirus and related diseases in the world. Summary Report 2021 Oct 22. https://hpvcentre.net/statistics/reports/XWX.pdf.
   Google Scholar
• World Health Organization. Global cancer observatory [accessed 2022 Apr 1]. https://gco.iarc.fr/.
   Google Scholar
• Kang YJ, Smith M, Canfell K. Anal cancer in high-income countries: increasing burden of disease. PLoS One. 2018;13(10):e0205105. doi:10.1371/journal.pone.0205105.
   PubMed Web of Science ®Google Scholar
• Silva Dalla Libera L, Almeida de Carvalho KP, Enocencio Porto Ramos J, Oliveira Cabral LA, de Cassia Goncalves de Alencar R, Villa LL, Alves RRF, Rabelo Santos SH, Aparecida Dos Santos Carneiro M, Saddi VA. Human papillomavirus and anal cancer: prevalence, genotype distribution, and prognosis aspects from Midwestern Region of Brazil. J Oncol. 2019;2019: 6018269. doi:10.1155/2019/6018269.
   PubMed Web of Science ®Google Scholar
• Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086. doi:10.1093/jnci/djv086.
   PubMedGoogle Scholar
• Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, et al. Association of immunosuppression and human immunodeficiency virus (HIV) viremia with anal cancer risk in persons living with HIV in the United States and Canada. Clin Infect Dis. 2020;70(6):1176–85. doi:10.1093/cid/ciz329.
   PubMed Web of Science ®Google Scholar
• Honaryar MK, Tarasenko Y, Almonte M, Smelov V. Epidemiology of cancers in men who have sex with men (MSM): a protocol for umbrella review of systematic reviews. Int J Environ Res Public Health. 2020;17(14):4954. doi:10.3390/ijerph17144954.
   PubMed Web of Science ®Google Scholar
• Wohlmuth C, Ghorab Z, Shier M, Tinmouth J, Salit IE, Covens A, Zhang L, Vicus D. Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer. Cancer Cytopathol. 2021;129(2):140–47. doi:10.1002/cncy.22360.
   PubMed Web of Science ®Google Scholar
• Lupi M, Brogden D, Howell A-M, Tekkis P, Mills S, Kontovounisios C. Anal cancer in high-risk women: the lost tribe. Cancers (Basel). 2023;15(1):60. doi:10.3390/cancers15010060.
   Web of Science ®Google Scholar
• Kim M-A, Han GH, Kim J-H, Seo K. Current status of human papillomavirus infection and introduction of vaccination to the national immunization program in Korea: an overview. J Korean Med Sci. 2018;33(52):e331. doi:10.3346/jkms.2018.33.e331.
   PubMed Web of Science ®Google Scholar
• Park HC, Jung KW, Kim BW, Shin A, Won YJ, Oh JH, Jeong SY, Yu CS, Lee BH. Characteristics and survival of Korean anal cancer from the Korea central cancer registry data. Ann Coloproctol. 2013;29(5):182–85. doi:10.3393/ac.2013.29.5.182.
   PubMedGoogle Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y, Suleimenova A, Shamkeeva S, Aimagambetova G. Prophylactic human papillomavirus vaccination: from the origin to the current state. Vaccines. 2022;10(11):1912. doi:10.3390/vaccines10111912.
   Web of Science ®Google Scholar
• Issanov A, Karim ME, Aimagambetova G, Dummer TJB. Does vaccination protect against human papillomavirus-related cancers? Preliminary findings from the United States national health and nutrition examination survey (2011–2018). Vaccines. 2022;10(12):2113. doi:10.3390/vaccines10122113.
   Web of Science ®Google Scholar
• National Immunization Program for children; 2022 [accessed 2022 Feb 1]. https://www.kdca.go.kr/contents.es?mid=a30333000000.
   Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–58. doi:10.4161/hv.7.12.18281.
   PubMed Web of Science ®Google Scholar
• Leung TF, Liu AP, Lim FS, Thollot F, Oh HML, Lee BW, Rombo L, Tan NC, Rouzier R, De Simoni S, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: results to month 36 from a randomized trial. Vaccine. 2018;36(1):98–106. doi:10.1016/j.vaccine.2017.11.034.
   PubMed Web of Science ®Google Scholar
• Bi D, Apter D, Eriksson T, Hokkanen M, Zima J, Damaso S, Soila M, Dubin G, Lehtinen M, Struyf F. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years. Hum Vaccin Immunother. 2020;16(6):1392–403. doi:10.1080/21645515.2019.1692557.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, Pukkala E, Angelo MG, Zima J, David MP, et al. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: interim analysis of a large community-randomized controlled trial. Hum Vaccin Immunother. 2016;12(12):3177–85. doi:10.1080/21645515.2016.1183847.
   PubMed Web of Science ®Google Scholar
• Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, Levänen H, Tocklin T, Godeaux O, Lehtinen M, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10–18 years. J Adolesc Health. 2009;44(1):33–40. doi:10.1016/j.jadohealth.2008.10.002.
   PubMed Web of Science ®Google Scholar
• Ministry of Food and Drug Safety. Drug details - cervarix prefilled syringe [accessed 2022 Aug 12]. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200807369.
   Google Scholar
• Setiawan D, Luttjeboer J, Pouwels KB, Wilschut JC, Postma MJ. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis. Jpn J Clin Oncol. 2017;47: 265–76. doi:10.1093/jjco/hyw192.
   PubMed Web of Science ®Google Scholar
• Kim C-J, Song R, Chen J, Tavares Da Silva F, Gopala KB, Kim JH, Bi D, Park JS. Six-year multi-centre, observational, post-marketing surveillance of the safety of the HPV-16/18 AS04-adjuvanted vaccine in women aged 10-25 years in Korea. Pharmacoepidemiol Drug Saf. 2017;26(7):837–42. doi:10.1002/pds.4175.
   PubMed Web of Science ®Google Scholar
• Yoon D, Lee J-H, Lee H, Shin J-Y. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study. BMJ. 2021;372: m4931. doi:10.1136/bmj.m4931.
   PubMedGoogle Scholar
• Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf. 2014;23(5):456–65. doi:10.1002/pds.3593.
   PubMed Web of Science ®Google Scholar
• Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5(5):332–40. doi:10.4161/hv.5.5.7211.
   PubMed Web of Science ®Google Scholar
• Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba, Pc, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62. doi:10.4161/hv.29532.
   PubMed Web of Science ®Google Scholar